McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X, Murziani, Paola, Slusarczyk, Magdalena ORCID: https://orcid.org/0000-0002-4707-7190, Gonczy, Blanka, Vande Voorde, Johan, Liekens, Sandra and Balzarini, Jan 2011. Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside. Journal of Medicinal Chemistry 54 (20) , pp. 7247-7258. 10.1021/jm200815w |
Abstract
The fluorinated pyrimidine family of nucleosides continues to represent major current chemotherapeutic agents for treating solid tumors. We herein report their phosphate prodrugs, ProTides, as promising new derivatives, which partially bypass the dependence of the current drugs on active transport and nucleoside kinase-mediated activation. They are also resistant to metabolic deactivation by phosphorolytic enzymes. We report 39 ProTides of the fluorinated pyrimidine FUDR with variation in the aryl, ester, and amino acid regions. Notably, only certain ProTide motifs are successful in delivering the nucleoside monophosphate into intact cells. We also find that the ProTides retain activity in mycoplasma infected cells, unlike FUDR. Data suggest these compounds to be worthy of further progression.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy Systems Immunity Research Institute (SIURI) |
Subjects: | Q Science > QD Chemistry R Medicine > RS Pharmacy and materia medica |
Publisher: | ACS Publications |
ISSN: | 0022-2623 |
Last Modified: | 18 Oct 2022 13:00 |
URI: | https://orca.cardiff.ac.uk/id/eprint/11977 |
Citation Data
Cited 89 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |